VDRM PR just out..Way undervalued imo >>LOS ANGELE
Post# of 98019
(Total Views: 127)
Posted On: 04/19/2017 11:45:58 AM
VDRM PR just out..Way undervalued imo >>LOS ANGELES, CA--(Marketwired - April 19, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that its President, Dr. Christopher Otiko's abstract, on the use of the Company's Viabecline, was well received by the "Medical and Professional" attendees at the DFCON Conference in Houston last month. The Company is in the final testing phase before manufacturing its Patent Pending (provisional patent number 62433964) topical antibiotic product, Viabecline. FDA registered Viabecline directly targets the affected area of the body by applying the medication onto the skin in an ointment based topical solution. Viabecline is registered with the FDA (NDC number 69006-002-00) as a first aid to treat cuts, scrapes and burns.
At DFCON, ViaDerma CEO Dr. Christopher Otiko presented a poster abstract of a study that showed Viabecline to be 96% effective in healing diabetic foot ulcers within 4 weeks. This is significant because a competing drug in recent Phase III Clinical trials did not meet the primary clinical endpoint of superiority versus placebo or which assessed the candidate in patients with mild infections of diabetic foot ulcers. The results of that clinical trial, which were also discussed extensively at DFCON, also showed that the competing drug did not show any meaningful difference in wound closure rate compared with vehicle, and neither trial met secondary endpoints of demonstrating a higher rate of eradication of bacteria for the drug vs the placebo. "These results are quite significant," said Otiko. "Viabecline has been well over 90% successful in treating diabetic foot infections. Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols which will save a lot of limbs and lives."
The Company has also filed with the FDA for it "Premature Ejaculation" product using Lidocaine and its proprietary solution to add men in maintaining an erection for twice as long during sexual intercourse. "We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko
At DFCON, ViaDerma CEO Dr. Christopher Otiko presented a poster abstract of a study that showed Viabecline to be 96% effective in healing diabetic foot ulcers within 4 weeks. This is significant because a competing drug in recent Phase III Clinical trials did not meet the primary clinical endpoint of superiority versus placebo or which assessed the candidate in patients with mild infections of diabetic foot ulcers. The results of that clinical trial, which were also discussed extensively at DFCON, also showed that the competing drug did not show any meaningful difference in wound closure rate compared with vehicle, and neither trial met secondary endpoints of demonstrating a higher rate of eradication of bacteria for the drug vs the placebo. "These results are quite significant," said Otiko. "Viabecline has been well over 90% successful in treating diabetic foot infections. Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols which will save a lot of limbs and lives."
The Company has also filed with the FDA for it "Premature Ejaculation" product using Lidocaine and its proprietary solution to add men in maintaining an erection for twice as long during sexual intercourse. "We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko
(0)
(0)Scroll down for more posts ▼